340 related articles for article (PubMed ID: 8687976)
1. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
2. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
5. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
7. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
[TBL] [Abstract][Full Text] [Related]
10. Bone turnover in children with vitamin D deficiency rickets before and during treatment.
Baroncelli GI; Bertelloni S; Ceccarelli C; Amato V; Saggese G
Acta Paediatr; 2000 May; 89(5):513-8. PubMed ID: 10852183
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.
Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J
Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513
[TBL] [Abstract][Full Text] [Related]
12. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
[TBL] [Abstract][Full Text] [Related]
15. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
[TBL] [Abstract][Full Text] [Related]
17. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
18. Paget's disease of bone treated with a five day course of oral tiludronate.
Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P
Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515
[TBL] [Abstract][Full Text] [Related]
19. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
20. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Lems WF; Gerrits MI; Jacobs JW; van Vugt RM; van Rijn HJ; Bijlsma JW
Ann Rheum Dis; 1996 May; 55(5):288-93. PubMed ID: 8660101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
